Advertisement
Article| Volume 46, ISSUE 3, P642-650, March 2023

Direct-to-consumer fertility testing: utilization and perceived utility among fertility patients and reproductive endocrinologists

Published:November 17, 2022DOI:https://doi.org/10.1016/j.rbmo.2022.11.007

      Abstract

      Research Question

      What is the utilization of direct-to-consumer fertility tests (DTCFT) among fertility patients? How does the perceived utility of DTCFT differ between patients and reproductive endocrinologists (REI)?

      Design

      Infertility patients visiting the Duke Fertility Center between December 2020 and December 2021 were sent an electronic invitation to participate in a patient survey. Members of the Society of Reproductive Endocrinology and Infertility were also sent e-mail invitations to participate in the REI survey. DTCFT were defined as tests not ordered by a physician or performed at a physician's office, including calendar methods of ovulation prediction, urinary ovulation prediction kits, basal body temperature (BBT) monitoring, hormone analysis, ovarian reserve testing and semen analysis. Patients and REI were asked how likely they were to recommend a given DTCFT, on a 0–10 Likert scale.

      Results

      In total, 425 patients (response rate 50.5%) and 178 REI (response rate 21.4%) completed the surveys. Patients reported the utilization of calendar methods of ovulation prediction (83.8%), urinary ovulation prediction (78.8%), BBT monitoring (30.8%), hormone analysis (15.3%), semen analysis (10.1%) and ovarian reserve testing (9.2%). REI rated the utility of all DTCFT significantly lower than patients did (average discordance –4.2, P < 0.001), except for urinary ovulation prediction, which REI gave a significantly higher score (discordance +1.0, P < 0.001). Prior pregnancy was significantly associated with home ovulation prediction utilization among patients (adjusted odds ratio 3.21, 95% confidence interval 1.2–9.83).

      Conclusions

      Methods of ovulation prediction are commonly used by fertility patients. Significant discordance exists in the perceived utility of DTCFT between patients and REI. Patient education and guidelines are needed to better inform individuals considering DTCFT.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Reproductive BioMedicine Online
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ali R.
        • Gurtin Z.B.
        • Harper J.C.
        Do fertility tracking applications offer women useful information about their fertile window?.
        Reprod. Biomed. Online. 2020;
        • Anon
        Acog committee opinion no. 773 summary: The use of antimullerian hormone in women not seeking fertility care.
        Obstet. Gynecol. 2019; 133: 840-841
        • Brezina P.R.
        • Haberl E.
        • Wallach E.
        At home testing: optimizing management for the infertility physician.
        Fertil. Steril. 2011; 95: 1867-1878
        • Broer S.L.
        • Broekmans F.J.
        • Laven J.S.
        • Fauser B.C.
        Anti-mullerian hormone: Ovarian reserve testing and its potential clinical implications.
        Hum. Reprod. Update. 2014; 20: 688-701
        • Colombo B.
        • Masarotto G.
        Daily fecundability: First results from a new data base.
        Demogr. Res. 2000; 3: 39
        • Costa Figueiredo M.
        • Huynh T.
        • Takei A.
        • Epstein D.A.
        • Chen Y.
        Goals, life events, and transitions: Examining fertility apps for holistic health tracking.
        JAMIA Open. 2021; 4 (ooab013)
        • Culley L.
        • Hudson N.
        • Lohan M.
        Where are all the men? The marginalization of men in social scientific research on infertility.
        Reprod. Biomed. Online. 2013; 27: 225-235
        • Demarest S.
        • Van Der Heyden J.
        • Charafeddine R.
        • Tafforeau J.
        • Van Oyen H.
        • Van Hal G.
        Socio-economic differences in participation of households in a belgian national health survey.
        Eur. J. Public Health. 2013; 23: 981-985
        • Duane M.
        • Contreras A.
        • Jensen E.T.
        • White A.
        The performance of fertility awareness-based method apps marketed to avoid pregnancy.
        J. Am. Board Fam. Med. 2016; 29: 508-511
        • Duane M.
        • Stanford J.B.
        • Porucznik C.A.
        • Vigil P.
        Fertility awareness-based methods for women's health and family planning.
        Front Med. (Lausanne). 2022; 9858977
        • Dundar Akin O.
        • Boza A.
        • Yakin K.
        • Urman B.
        Awareness of fertility and reproductive aging in women seeking oocyte cryopreservation, reproductive aged controls, and female health care professionals: A comparative study.
        Eur. J. Obstet. Gynecol. Reprod. Biol. 2019; 233: 146-150
        • Dunson D.B.
        • Baird D.D.
        • Wilcox A.J.
        • Weinberg C.R.
        Day-specific probabilities of clinical pregnancy based on two studies with imperfect measures of ovulation.
        Hum. Reprod. 1999; 14: 1835-1839
        • Firth D.
        Bias reduction of maximum likelihood estimates.
        Biometrika. 1993; 80: 27-38
        • Freis A.
        • Freundl-Schutt T.
        • Wallwiener L.M.
        • Baur S.
        • Strowitzki T.
        • Freundl G.
        • Frank-Herrmann P.
        Plausibility of menstrual cycle apps claiming to support conception.
        Front Public Health. 2018; 6: 98
        • Gim T.-H.T.
        • Ko J.
        Maximum likelihood and firth logistic regression of the pedestrian route choice.
        International Regional Science Review. 2017; 40: 616-637
        • Gonzalez D.
        • Narasimman M.
        • Best J.C.
        • Ory J.
        • Ramasamy R.
        Clinical update on home testing for male fertility.
        World J. Mens Health. 2021; 39: 615-625
        • Goodman L.R.
        • Balthazar U.
        • Kim J.
        • Mersereau J.E.
        Trends of socioeconomic disparities in referral patterns for fertility preservation consultation.
        Hum. Reprod. 2012; 27: 2076-2081
        • Isbell T.S.
        Direct-to-consumer tests on the market today: Identifying valuable tests from those with limited utility.
        Clin. Lab. Med. 2020; 40: 13-23
        • Jain T.
        Socioeconomic and racial disparities among infertility patients seeking care.
        Fertil. Steril. 2006; 85: 876-881
        • Jones G.
        • Carlton J.
        • Weddell S.
        • Johnson S.
        • Ledger W.L.
        Women's experiences of ovulation testing: A qualitative analysis.
        Reprod. Health. 2015; 12: 116
      1. Kennedy, K., 2020. Od4036: Fertility clinics. US Specialized Industry Reports. IBIS World.

        • Keulers M.J.
        • Hamilton C.J.
        • Franx A.
        • Evers J.L.
        • Bots R.S.
        The length of the fertile window is associated with the chance of spontaneously conceiving an ongoing pregnancy in subfertile couples.
        Hum. Reprod. 2007; 22: 1652-1656
        • Kobori Y.
        Home testing for male factor infertility: A review of current options.
        Fertil. Steril. 2019; 111: 864-870
        • Korkeila K.
        • Suominen S.
        • Ahvenainen J.
        • Ojanlatva A.
        • Rautava P.
        • Helenius H.
        • Koskenvuo M.
        Non-response and related factors in a nation-wide health survey.
        Eur. J. Epidemiol. 2001; 17: 991-999
        • Kraus R.
        Hounded by fertility ads on instagram? Don't let them stress you out.
        Health & Wellness. Mashable.com. 2021;
        • Kyweluk M.A.
        Quantifying fertility? Direct-to-consumer ovarian reserve testing and the new (in)fertility pipeline.
        Soc. Sci. Med. 2020; 245112697
        • Kyweluk M.A.
        • Feinberg E.C.
        Direct-to-consumer (dtc) ovarian reserve testing benefits the company, not the consumer. Consider This.
        American Society for Reproductive Medicine (ASRM): Fertilty & Sterility, 2020
        • Liang B.A.
        • Mackey T.
        Reforming direct-to-consumer advertising.
        Nat. Biotechnol. 2011; 29: 397-400
        • Lovett K.M.
        • Mackey T.K.
        • Liang B.A.
        Evaluating the evidence: Direct-to-consumer screening tests advertised online.
        J. Med. Screen. 2012; 19: 141-153
        • Manders M.
        • Mclindon L.
        • Schulze B.
        • Beckmann M.M.
        • Kremer J.A.
        • Farquhar C.
        Timed intercourse for couples trying to conceive.
        Cochrane Database Syst. Rev. 2015; (CD011345)
        • Practice Committee of the American Society for Reproductive
        Diagnostic evaluation of the infertile female: A committee opinion.
        Fertil. Steril. 2015; 103: e44-e50
        • Practice Committee of the American Society for Reproductive Medicine
        Definitions of infertility and recurrent pregnancy loss: A committee opinion.
        Fertil. Steril. 2020; 113: 533-535
        • Practice Committee of the American Society for Reproductive Medicine. Electronic Address, A.a.O., Practice Committee of the American Society for Reproductive
        Testing and interpreting measures of ovarian reserve: A committee opinion.
        Fertil. Steril. 2020; 114: 1151-1157
        • Reinikainen J.
        • Tolonen H.
        • Borodulin K.
        • Harkanen T.
        • Jousilahti P.
        • Karvanen J.
        • Koskinen S.
        • Kuulasmaa K.
        • Mannisto S.
        • Rissanen H.
        • Vartiainen E.
        Participation rates by educational levels have diverged during 25 years in finnish health examination surveys.
        Eur. J. Public Health. 2018; 28: 237-243
        • Robinson J.E.
        • Wakelin M.
        • Ellis J.E.
        Increased pregnancy rate with use of the clearblue easy fertility monitor.
        Fertil. Steril. 2007; 87: 329-334
        • Setton R.
        • Tierney C.
        • Tsai T.
        The accuracy of web sites and cellular phone applications in predicting the fertile window.
        Obstet. Gynecol. 2016; 128: 58-63
        • Spitzer S.
        Biases in health expectancies due to educational differences in survey participation of older europeans: It's worth weighting for.
        Eur. J. Health Econ. 2020; 21: 573-605
        • Stanford J.B.
        • Willis S.K.
        • Hatch E.E.
        • Rothman K.J.
        • Wise L.A.
        Fecundability in relation to use of fertility awareness indicators in a north american preconception cohort study.
        Fertil. Steril. 2019; 112: 892-899
        • Steiner A.Z.
        • Pritchard D.
        • Stanczyk F.Z.
        • Kesner J.S.
        • Meadows J.W.
        • Herring A.H.
        • Baird D.D.
        Association between biomarkers of ovarian reserve and infertility among older women of reproductive age.
        JAMA. 2017; 318: 1367-1376
        • Tal R.
        • Seifer D.B.
        Ovarian reserve testing: A user's guide.
        Am. J. Obstet. Gynecol. 2017; 217: 129-140
        • Tsao Y.T.
        • Yang C.Y.
        • Wen Y.C.
        • Chang T.C.
        • Matsuura K.
        • Chen Y.
        • Cheng C.M.
        Point-of-care semen analysis of patients with infertility via smartphone and colorimetric paper-based diagnostic device.
        Bioeng Transl. Med. 2021; 6: e10176
        • Turi J.B.
        Vc investment soars for fertility services even as birthrate dips. Health.
        Wellness & Biotech. Crunchbase.com. 2021;
      2. United States Food and Drug Administration, 2019. Direct-to-consumer tests. Medical Devices: In Vitro Diagnostics. FDA.gov.

        • Wilcox A.J.
        • Weinberg C.R.
        • Baird D.D.
        Timing of sexual intercourse in relation to ovulation. Effects on the probability of conception, survival of the pregnancy, and sex of the baby.
        N. Engl. J. Med. 1995; 333: 1517-1521
        • Yeh P.T.
        • Kennedy C.E.
        • Van Der Poel S.
        • Matsaseng T.
        • Bernard L.
        • Narasimhan M.
        Should home-based ovulation predictor kits be offered as an additional approach for fertility management for women and couples desiring pregnancy? A systematic review and meta-analysis.
        BMJ Glob Health. 2019; 4e001403
        • Yu S.
        • Rubin M.
        • Geevarughese S.
        • Pino J.S.
        • Rodriguez H.F.
        • Asghar W.
        Emerging technologies for home-based semen analysis.
        Andrology. 2018; 6: 10-19

      Biography

      Benjamin J. Peipert, MD, is the Education Chief Resident in Obstetrics and Gynaecology at Duke University, USA. Ben is a passionate provider and advocate, research interests including access to care, medical innovation and health policy. After his residency, he will start his fellowship in Reproductive Endocrinology and Infertility at the University of Pennsylvania, USA.
      Key message
      Ovulation prediction tests are commonly used among fertility patients. Reproductive endocrinologists gave significantly lower utility scores for all forms of direct-to-consumer fertility testing compared with patients, except for urinary ovulation prediction. Patient education and guidelines are needed to better inform individuals considering direct-to-consumer fertility tests.